Article Text

Download PDFPDF

5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study.
  1. J A Casas,
  2. P A Saway,
  3. I Villarreal,
  4. C Nolte,
  5. B L Menajovsky,
  6. E E Escudero,
  7. W D Blackburn,
  8. G S Alarcón,
  9. C P Subauste
  1. Department of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.


    A six month controlled study of 5-fluorouracil in the treatment of scleroderma showed a modest benefit in skin scores, Raynaud's phenomenon, and patients' global assessment. Visceral organ and hand function were unaffected. Mild to moderate toxicity was common in the 5-fluorouracil treated patients but usually responded to dose reduction. Two patients receiving 5-fluorouracil died from causes seemingly unrelated to treatment. Significant clinical improvement in scleroderma was not noted in the first six months of treatment with 5-fluorouracil.

    Statistics from

    Supplementary materials

    Related Data

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.